Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 336

1.

Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis.

Cooper KL, Madan J, Whyte S, Stevenson MD, Akehurst RL.

BMC Cancer. 2011 Sep 23;11:404. doi: 10.1186/1471-2407-11-404. Review.

2.

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.

Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, Lyman GH, Pettengell R, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C; European Organisation for Research and Treatment of Cancer.

Eur J Cancer. 2011 Jan;47(1):8-32. doi: 10.1016/j.ejca.2010.10.013. Epub 2010 Nov 20.

PMID:
21095116
3.

Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study.

Tan H, Tomic K, Hurley D, Daniel G, Barron R, Malin J.

Curr Med Res Opin. 2011 Jan;27(1):79-86. doi: 10.1185/03007995.2010.536527. Epub 2010 Nov 22.

PMID:
21091127
4.

Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: A systematic review.

Mitchell S, Li X, Woods M, Garcia J, Hebard-Massey K, Barron R, Samuel M.

J Oncol Pharm Pract. 2016 Oct;22(5):702-16. doi: 10.1177/1078155215625459. Epub 2016 Jan 13. Review.

PMID:
26769697
5.

The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials.

Wang L, Baser O, Kutikova L, Page JH, Barron R.

Support Care Cancer. 2015 Nov;23(11):3131-40. doi: 10.1007/s00520-015-2686-9. Epub 2015 Mar 29. Review.

6.

Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients.

Renner P, Milazzo S, Liu JP, Zwahlen M, Birkmann J, Horneber M.

Cochrane Database Syst Rev. 2012 Oct 17;10:CD007913. doi: 10.1002/14651858.CD007913.pub2. Review.

7.

Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States.

Lyman G, Lalla A, Barron R, Dubois RW.

Curr Med Res Opin. 2009 Feb;25(2):401-11. doi: 10.1185/03007990802636817 .

PMID:
19192985
8.

Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain--results of the LEARN Study.

Almenar D, Mayans J, Juan O, Bueno JM, Lopez JI, Frau A, Guinot M, Cerezuela P, Buscalla EG, Gasquet JA, Sanchez J.

Eur J Cancer Care (Engl). 2009 May;18(3):280-6. doi: 10.1111/j.1365-2354.2008.00959.x. Epub 2008 Dec 8.

9.

EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours.

Aapro MS, Cameron DA, Pettengell R, Bohlius J, Crawford J, Ellis M, Kearney N, Lyman GH, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C; European Organisation for Research and Treatment of Cancer (EORTC) Granulocyte Colony-Stimulating Factor (G-CSF) Guidelines Working Party.

Eur J Cancer. 2006 Oct;42(15):2433-53. Epub 2006 Jun 5. Review.

PMID:
16750358
11.

Cost-effectiveness of granulocyte colony-stimulating factor prophylaxis for febrile neutropenia in breast cancer in the United Kingdom.

Whyte S, Cooper KL, Stevenson MD, Madan J, Akehurst R.

Value Health. 2011 Jun;14(4):465-74. doi: 10.1016/j.jval.2010.10.037. Epub 2011 Apr 22.

12.

Cost-effectiveness of filgrastim and pegfilgrastim as primary prophylaxis against febrile neutropenia in lymphoma patients.

Lathia N, Isogai PK, De Angelis C, Smith TJ, Cheung M, Mittmann N, Hoch JS, Walker S.

J Natl Cancer Inst. 2013 Aug 7;105(15):1078-85. doi: 10.1093/jnci/djt182. Epub 2013 Jul 19.

PMID:
23873405
13.

Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review.

Pfeil AM, Allcott K, Pettengell R, von Minckwitz G, Schwenkglenks M, Szabo Z.

Support Care Cancer. 2015 Feb;23(2):525-45. doi: 10.1007/s00520-014-2457-z. Epub 2014 Oct 7. Review.

PMID:
25284721
14.

The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients with breast cancer in the UK.

Liu Z, Doan QV, Malin J, Leonard R.

Appl Health Econ Health Policy. 2009;7(3):193-205. doi: 10.2165/11314740-000000000-00000.

PMID:
19799473
15.

Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia.

Heaney ML, Toy EL, Vekeman F, Laliberté F, Dority BL, Perlman D, Barghout V, Duh MS.

Cancer. 2009 Oct 15;115(20):4839-48. doi: 10.1002/cncr.24535.

16.
18.

Use of filgrastim and pegfilgrastim to support delivery of chemotherapy: twenty years of clinical experience.

Renwick W, Pettengell R, Green M.

BioDrugs. 2009;23(3):175-86. doi: 10.2165/00063030-200923030-00004. Review.

PMID:
19627169
19.

[Pegfilgrastim vs filgrastim in primary prophylaxis of febrile neutropenia in patients with breast cancer after chemotherapy: a cost-effectiveness analysis for Germany].

Sehouli J, Goertz A, Steinle T, Dubois R, Plesnila-Frank C, Lalla A, von Minckwitz G.

Dtsch Med Wochenschr. 2010 Mar;135(9):385-9. doi: 10.1055/s-0030-1249174. Epub 2010 Feb 23. German.

PMID:
20180162
20.

Supplemental Content

Support Center